MEI PHARMA
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myelo... id leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
MEI PHARMA
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2000-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.meipharma.com
Total Employee:
11+
Status:
Active
Contact:
858-792-6300
Email Addresses:
[email protected]
Total Funding:
160.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Content Delivery Network Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
CAM Capital
CAM Capital investment in Post-IPO Equity - MEI Pharma
Vivo Capital
Vivo Capital investment in Post-IPO Equity - MEI Pharma
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - MEI Pharma
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - MEI Pharma
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - MEI Pharma
Boxer Capital
Boxer Capital investment in Post-IPO Equity - MEI Pharma
Amzak Health Investors
Amzak Health Investors investment in Post-IPO Equity - MEI Pharma
3B Future Health Fund
3B Future Health Fund investment in Post-IPO Equity - MEI Pharma
RA Capital Management
RA Capital Management investment in Post-IPO Equity - MEI Pharma
Vivo Capital
Vivo Capital investment in Post-IPO Equity - MEI Pharma
Key Employee Changes
Official Site Inspections
http://www.meipharma.com Semrush global rank: 2.03 M Semrush visits lastest month: 10.38 K
- Host name: 104.21.28.137
- IP address: 104.21.28.137
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MEI Pharma"
Homepage | MEI Pharma
Aug 12, 2024 · Sep 19, 2024. MEI Pharma Reports Fiscal Year End 2024 Cash Position. Read more. Aug 12, 2024. MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating …See details»
About MEI Pharma | MEI Pharma
Home. About MEI Pharma. We are a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.See details»
Board of Directors - MEI Pharma
Dr. Glover has been a director of MEI Pharma since June 2013. He is currently a consultant to the biotech industry.See details»
Our Focus - MEI Pharma
Our Focus. Striving for Best-in-Class. We strive to develop novel and differentiated cancer therapies in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to …See details»
MEI Pharma - LinkedIn
MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes...See details»
MEI Pharma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 858-792-6300 MEI Pharma is a oncology company focused on the clinical development of novel therapies for cancer.See details»
MEI Pharma - Overview, News & Similar companies | ZoomInfo.com
May 9, 2024 · View MEI Pharma (www.meipharma.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
| MEI Pharma
… Next page›. » The Investor Relations website contains information about MEI Pharma's business for stockholders, potential investors, and financial analysts.See details»
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and ...
Dec 31, 2023 · MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer therapies. We build our pipeline by …See details»
MEI Pharma Company Profile 2024: Stock Performance …
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute …See details»
Careers - MEI Pharma
MEI Pharma’s team is made up of passionate and innovative individuals who are committed to building a better future for our patients. We believe that science and technology has the power to solve the world's biggest problems. We are …See details»
MEI Pharma and Infinity Pharmaceuticals Announce Definitive …
Feb 23, 2023 · The combined organization will have three differentiated clinical-stage oncology assets, expected funding into mid-2025 to reach clinical data in all three programs, and a team …See details»
MEI Pharma Initiates Strategic Realignment
MEIP plans to streamline its organization towards the continued clinical development of voruciclib and ME-344. As a result, it plans to initiate a staggered workforce reduction, initially …See details»
MEI Pharma to Present at the 2021 Cantor Virtual Global …
SAN DIEGO, Sept. 22, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced …See details»
Pipeline - MEI Pharma
Pipeline | MEI Pharma. Home. Pipeline. Overview. Our pipeline includes clinical-stage drug candidates each with its own unique mechanism of action that can target pathways involved in …See details»
MEI Pharma Initiates Strategic Realignment - Business Wire
Dec 5, 2022 · As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib and ME-344.See details»
Release Details - investor.meipharma.com
Sep 21, 2023 · MEI Pharma’s portfolio of drug candidates includes clinical stage candidates with differentiated mechanisms of action intended to address unmet medical needs and deliver …See details»
MEI Pharma - Craft
Sep 6, 2024 · MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug …See details»
Press Releases - MEI Pharma
Date Title Download; Dec 6 2021: MEI Pharma Announces Closing of Public Offering of Common Stock: PDF: Dec 3 2021: MEI Pharma Announces Inducement Grant Under Nasdaq Listing …See details»
MEI Pharma to present at the 20th Annual Needham Virtual …
SAN DIEGO, April 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its …See details»